Cipla launches skin treatment Daptomycin Injection in US
Also read:- Cipla employee settles case with SEBI, pays Rs 3 lakh
"Cipla and its subsidiary Cipla USA, Inc announce the launch of Daptomycin for Injection, 500mg/vial, single-dose vial, AP-rated generic equivalent of Cubicin for Injection in the US," the statement said.
Also read:- Cipla arm, Novartis enter agreement for Ultibro Breezhaler to treat COPD
According to IQVIA Health, Cubicin injection brand and generics had sales of around USD 606 million for the most recent 12 months ending in June 2019.
Also read:- Cipla API facility in Bengaluru gets EIR from USFDA
"The product is available for shipping immediately," the statement said.
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at email@example.com. Check out more about our bureau/team here